$34 Million is the total value of Healthcare Value Capital, LLC's 16 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 45.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GSK | GLAXOSMITHKLINE PLCsponsored adr | $4,699,000 | +10.1% | 100,000 | 0.0% | 13.83% | +79.4% | |
| GILD | GILEAD SCIENCES INC | $4,549,000 | +2.5% | 70,000 | 0.0% | 13.39% | +67.1% | |
| ABBV | ABBVIE INC | $4,427,000 | +16.9% | 50,000 | 0.0% | 13.03% | +90.6% | |
| CVS | CVS HEALTH CORP | $3,715,000 | +17.8% | 50,000 | 0.0% | 10.94% | +92.0% | |
| TYME | TYME TECHNOLOGIES INC | $3,045,000 | +17.7% | 2,175,000 | 0.0% | 8.96% | +91.8% | |
| VKTX | VIKING THERAPEUTICS INC | $2,005,000 | +16.6% | 250,000 | 0.0% | 5.90% | +90.0% | |
| CAH | CARDINAL HEALTH INC | $1,770,000 | +7.1% | 35,000 | 0.0% | 5.21% | +74.6% | |
| ABC | AMERISOURCEBERGEN CORP | $1,700,000 | +3.2% | 20,000 | 0.0% | 5.00% | +68.2% | |
| CLVS | Sell | CLOVIS ONCOLOGY INC | $1,564,000 | +59.1% | 150,000 | -40.0% | 4.60% | +159.4% |
| ATRS | Buy | ANTARES PHARMA INC | $1,410,000 | +110.8% | 300,000 | +50.0% | 4.15% | +243.6% |
| MCK | MCKESSON CORP | $1,383,000 | +1.2% | 10,000 | 0.0% | 4.07% | +64.9% | |
| FOMX | Buy | FOAMIX PHARMACEUTICALS LTD | $1,166,000 | +53.4% | 350,000 | +40.0% | 3.43% | +150.0% |
| CLVS | New | CLOVIS ONCOLOGY INCcall | $1,043,000 | – | 100,000 | +100.0% | 3.07% | – |
| ADMS | New | ADAMAS PHARMACEUTICALS INCcall | $758,000 | – | 200,000 | +100.0% | 2.23% | – |
| GNLN | Sell | GREENLANE HLDGS INCcl a | $570,000 | -15.9% | 175,000 | -12.5% | 1.68% | +37.0% |
| FOMX | FOAMIX PHARMACEUTICALS LTDcall | $167,000 | +9.9% | 50,000 | 0.0% | 0.49% | +78.9% | |
| TYME | Exit | TYME TECHNOLOGIES INCcall | $0 | – | -100,000 | -100.0% | -0.22% | – |
| ATRS | Exit | ANTARES PHARMA INCcall | $0 | – | -200,000 | -100.0% | -1.21% | – |
| NVLNF | Exit | NOVELION THERAPEUTICS INC | $0 | – | -1,400,000 | -100.0% | -1.83% | – |
| ADMS | Exit | ADAMAS PHARMACEUTICALS INC | $0 | – | -200,000 | -100.0% | -1.85% | – |
| WBA | Exit | WALGREENS BOOTS ALLIANCE INC | $0 | – | -50,000 | -100.0% | -5.00% | – |
| GILD | Exit | GILEAD SCIENCES INCcall | $0 | – | -50,000 | -100.0% | -5.72% | – |
| VIXY | Exit | PROSHARES TR IIcall | $0 | – | -200,000 | -100.0% | -7.05% | – |
| SPY | Exit | SPDR S&P 500 ETF TRput | $0 | – | -50,000 | -100.0% | -26.80% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GILEAD SCIENCES INC | 20 | Q3 2021 | 31.3% |
| GLAXOSMITHKLINE PLC | 20 | Q3 2021 | 16.1% |
| PFIZER INC | 19 | Q3 2021 | 17.9% |
| TYME TECHNOLOGIES INC | 17 | Q3 2021 | 40.3% |
| ASTRAZENECA PLC | 14 | Q3 2021 | 12.9% |
| QUEST DIAGNOSTICS INC | 14 | Q3 2016 | 9.5% |
| CRYOLIFE INC | 13 | Q1 2017 | 6.6% |
| ANTARES PHARMA INC | 13 | Q3 2021 | 6.7% |
| AMARIN CORP PLC | 13 | Q3 2021 | 4.9% |
| CYTOKINETICS INC | 13 | Q3 2016 | 1.7% |
View Healthcare Value Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| NOVELION THERAPEUTICS INC. | September 20, 2019 | 1,400,000 | 7.4% |
View Healthcare Value Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2021-11-15 |
| 13F-HR | 2021-08-16 |
| 13F-HR | 2021-05-17 |
| 13F-HR | 2021-02-16 |
| 13F-HR | 2020-11-16 |
| 13F-HR | 2020-08-14 |
| 13F-HR | 2020-05-15 |
| 13F-HR | 2020-02-14 |
| 13F-HR | 2019-11-14 |
| SC 13D/A | 2019-09-20 |
View Healthcare Value Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.